Oncology Venture - Three active trials with two more on the horizon
Oncology Venture (OV) recently included the first patient in its irofulven Phase II trial in prostate cancer, marking its third currently active trial. OV is also planning to initiate its second 2X-121 Phase II trial in ovarian cancer at the beginning of next year. Moreover, the company recently submitted pre-IDE/IND paperwork to the US FDA as it is seeking approval for LiPLaCis via a single-arm pivotal study in ~100-200 patients. The recent debt deal of ~SEK200m should fund OV’s current clinical development.Oncology Venture A/S, formerly known as Medical Prognosis Institute A/S, is a Denmark-based company engaged in the development of anticancer medicines. It is primarily focused on the tool development for identification of patients with the highest probability of responding to a particular drug candidate, which increases the chance that the drug candidate is to be successful in clinical trials. The Company aims to improve the response rate of anticancer medicines whose clinical development has been suspended. After the clinical trials, the Company is to out-license or sell the drug candidates with a high response rate. The Company's main drug candidates are comprised of APO010, Irofulven and LiPlaCis.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.